Compare Mesoblast Limited (MESO) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Procter & Gamble Co — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Procter & Gamble Co trades at $148.8 (market cap $347.26B). The key difference: Procter & Gamble Co is far larger — about 160× Mesoblast Limited's market cap, and Procter & Gamble Co pays a 2.92% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | PG | |
|---|---|---|
Market Cap | $2.17B | $347.26B |
Sector | Technology | Consumer Staples |
52-Week High | $20.96 | $167.18 |
52-Week Low | $12.88 | $138.10 |
Enterprise Value | $2.17B | $372.74B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Procter & Gamble (PG) trades at $149.96, down 1.0% on the day, with a bullish technical signal supported by moving averages. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS expected at $1.41. Revenue reached $84.28 billion in 2025, with a net income margin of 19.16%. Recent news highlights PG's dividend reliability and a new WNBA partnership, while analyst consensus leans bullish with a $161.71 price target.
PG offers stable growth and dividend income, supported by strong cash flow and brand strength. Risks include premium valuation concerns and soft demand outlook. Upside potential exists if earnings continue to exceed expectations, but investors should monitor margin pressures and competitive dynamics in consumer goods.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
